EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Camurus AB (CAMRF) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of Camurus AB $67.93, price $61.75, upside +10.0%, quality 72 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · ISIN SE0007692850

CA Camurus AB logo Broad data Sep 24, 2026

Camurus AB

CAMRF · US

NeutralQuality growthThe stock looks roughly fairly valued with average quality.

·Fair value $67.93 · Fairly valued (+10.0%)
✓Quality 72/100
✓Healthy Growth (revenue 5y +46.5 %/yr)
✓Highly profitable · 30.5% net margin (TTM)
✓Low debt · generates free cash flow
✓Wide moat 79/100

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$71.00 $0.0001 Fair Value $67.93 Dec 2017 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $0.0001 – $71.00 · fair‑value band $41.95 – $121.38 · the $61.75 price screens below the $67.93 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder.

Show more

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and is under phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 for the treatment of pulmonary arterial hypertension, as well as in phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; NewBridge Pharmaceuticals; and Eli Lilly for the development of long-acting incretin medicines based on FluidCrystal technology. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.

Stock analysis

Camurus AB (CAMRF) currently trades at $61.75, while our model-based Fair Value estimate is $67.93, implying the stock looks roughly 9.1% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $57.18 per share, and 0 of the 24 models we run sit above the $61.75 price.

Bear case: the Economic Profit group reads lowest at $10.43, and 24 of the 24 models stay below the price. Evidence for this calculation is high.

Scenario range: $41.95 (bear) to $121.38 (bull), the price of $61.75 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 72/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Camurus AB reported revenue of 2.3B SEK in FY2025 versus 601M SEK in FY2021, a compound +39.4%/yr. Reported net income was 736M SEK in FY2025.

Key figures

Market cap $3.7B · P/E ratio 51.0 · P/S ratio 16.6 · EPS (TTM) $1.21 · Net margin 32.5% · Return on equity 17.3% · Return on assets (EBIT) 10.8% · Revenue (TTM) 2.4B SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 58 out of 100 (medium confidence).

What moves the price

The share trades about 13% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 10%, CAMRF screens cheaper than that median.

Fair Value models

Bear $41.95 Fair Value $67.93 Bull $121.38
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.9150 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $25.82 $36.39 $69.34 75
EPV $18.20 $20.09 $21.72 74
Growth DCF $24.63 $41.24 $68.01 74
All 24 models by family
DCF Models
FCF DCF $25.82 $36.39 $69.34 75
Owner Earnings $21.82 $40.77 $79.09 70
5Y Revenue Exit $18.13 $25.56 $41.00 69
5Y EBITDA Exit $23.49 $36.40 $61.69 71
5Y P/E Exit $26.83 $52.40 $87.28 66
10Y Revenue Exit $20.28 $34.08 $41.93 65
10Y EBITDA Exit $24.45 $45.37 $81.37 63
10Y P/E Exit $26.83 $52.38 $94.41 59
Earnings-Based
Graham-Dodd $8.37 $58.37 $81.91 61
Lynch FV $30.16 $43.08 $56.00 59
PEG = 1.0 $30.16 $43.08 $56.00 55
EPV $18.20 $20.09 $21.72 74
Multiples
P/E Multiple $20.31 $27.08 $33.85 63
P/S Multiple $9.95 $13.27 $16.58 58
P/B Multiple $15.69 $20.92 $26.16 55
EV/EBIT $24.88 $31.09 $37.31 66
EV/EBITDA $22.03 $27.29 $32.56 67
EV/Revenue $14.20 $17.61 $21.02 54
Asset-Based
NCAV (Graham) $3.54 $4.75 $7.09 54
Growth DCF
Growth DCF $24.63 $41.24 $68.01 74
Rev-Margin DCF $19.29 $28.36 $47.42 69
Economic Profit
Residual Income $7.85 $10.43 $17.43 66
ROIC Compounder $19.33 $23.00 $27.09 70
Growth Earnings
Growth-Adj P/E $40.03 $57.18 $74.34 65

Open the full fair value analysis →

Notify me when CAMRF reaches fair value

Put CAMRF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 72/100

Of which business quality 73 · Market factors (momentum, volatility) 42

Profitability 73
Margins and returns on capital today
Quality Growth 67
Are margins and returns improving?
Cashflow 82
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 26
Disciplined investing over empire-building
Low Volatility 72
Calm price path (market factor)
Momentum 29
Price trend over the last 3–12 months (market factor)
52W Momentum 32
Distance to the 52-week high (market factor)
Net Issuance 63
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+21.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+46.5%
Start year 2020 (pandemic). Over 10 years: +30.8% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.2%
What shareholders gained per year (last 3 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+97.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+97.8%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−62% → 39%
2025 sits 70% above its own trend. The rate follows the median trend of the last 3 years, not that single year.

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+23.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+35.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in SEK, Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about +21.0% a year for the price and +33.2% for the forecasts.
Forecast 2026 (sales)+24.2%
Forecast 2027 (sales)+47.6%
Projected 2028 (sales)+41.9%
Projected 2029 (sales)+36.2%
Projected 2030 (sales)+30.5%

Watch CAMRF, get fair value alerts →

Compare Camurus AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Camurus AB · Fair Value
$67.93 +9%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Camurus AB Fair Value". https://www.fairvalue-calculator.com/stock/CAMRF

Frequently asked questions

Is Camurus AB (CAMRF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $67.93 versus the last price from Sep 25, 2026 of $61.75, about +10% upside (undervalued).
What is the fair value of CAMRF?
Our model-based fair value for Camurus AB is $67.93 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $61.75.
What is the quality score of CAMRF?
Camurus AB has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Camurus AB (CAMRF)?
Our model-based price target is the fair value of $67.93 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $41.95, optimistic scenario $121.38. It is a calculation from audited fundamentals, not an analyst target.
What is the Camurus AB stock forecast for 2026?
Our models put fair value at $67.93, about +10% upside versus the last price from Sep 25, 2026 of $61.75 (undervalued). Cautious scenario $41.95, optimistic scenario $121.38. The calculation is refreshed regularly with new filings.
What is the revenue of Camurus AB (CAMRF)?
Camurus AB reported trailing-twelve-month revenue of about 2.4B SEK (latest available figure, as of Sep 24, 2026).
What growth is priced into Camurus AB (CAMRF)?
For today's price to be fair in a discounted-cash-flow model, Camurus AB would have to grow free cash flow by +23.4 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +46.5 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of CAMRF use?
Our models discount Camurus AB at 8.5 %: a base by market capitalisation (mid), damped by beta 0.50, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Camurus AB that is +23.4 % per year a year over ten years, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Camurus AB (CAMRF) delivered so far?
Over the past 5 years revenue at Camurus AB grew +46.5 % a year. The price currently implies +23.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Camurus AB (CAMRF) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into Camurus AB (+23.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Camurus AB (CAMRF)?
The free-cash-flow yield on the price is 1.98 %: that much free cash flow Camurus AB produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Camurus AB (CAMRF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Camurus AB it is $67.93 per share (as of Sep 24, 2026), against a price of $61.75. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Camurus AB stock overvalued or undervalued in 2026?
As of Sep 24, 2026, CAMRF trades below its calculated fair value: price $61.75, fair value $67.93, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CAMRF?
No. The price is what the market pays today ($61.75); the fair value is what the company's own numbers justify ($67.93). For Camurus AB the two are $6.18 per share apart. That gap is exactly why we show both numbers side by side.
How much is Camurus AB worth?
The market values Camurus AB at about $3.7B (market capitalisation, as of Sep 24, 2026). Per share that is $61.75; our models calculate a fair value of $67.93 per share.
What do the bullish and bearish scenarios say about CAMRF?
Our models span a range for Camurus AB: cautious scenario $41.95, base $67.93, optimistic $121.38 per share (as of Sep 24, 2026, price $61.75). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is CAMRF from its 52-week high?
Camurus AB trades at $61.75, about 13% below its 52-week high of $71.00 and 14% above the low of $54.00 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $67.93 is for.
Which stocks are comparable to Camurus AB?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Camurus AB stock attractive at the current price?
The data as of Sep 24, 2026: price $61.75, calculated fair value $67.93 (+10%), Quality Score 72/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CAMRF calculated?
We run Camurus AB through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $67.93, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Camurus AB currently trades 9 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Camurus AB (CAMRF)?
The latest price we hold is from Sep 25, 2026 and stands at $61.75. Our model-based fair value is $67.93, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Camurus AB right now?
The model range is unusually wide ($41.95 to $121.38). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.

Key figures of Camurus AB

How large is the market capitalisation of Camurus AB (CAMRF)?
The market capitalisation of Camurus AB is $3.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Camurus AB (CAMRF)?
The price-to-earnings ratio of Camurus AB is 51.0. Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Camurus AB (CAMRF)?
The price-to-sales ratio of Camurus AB is 16.6 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Camurus AB (CAMRF)?
Earnings per share at Camurus AB are $1.21 (price ÷ EPS = P/E 51.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Camurus AB (CAMRF)?
The net margin of Camurus AB is 32.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Camurus AB (CAMRF)?
The return on equity (ROE) of Camurus AB is 17.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Camurus AB (CAMRF)?
On an EBIT basis the return on assets of Camurus AB is 10.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Camurus AB (CAMRF)?
Revenue at Camurus AB is growing −4.5% versus a year earlier (3y avg +33.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Camurus AB (CAMRF)?
Earnings per share at Camurus AB are growing −27.1% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Continue in the live analysis

Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.